IL-1 trap for rheumatoid arthritis: full speed ahead.
Since the highest dose studied--100 mg once weekly by subcutaneous injection--was the most effective and was also relatively well tolerated, future trials will explore higher doses, Clifford O. Bingham III, M.D., said at the annual European Congress of Rheumatology.
Interleukin-1 (IL-1) is a key cytokine in rheumatoid arthritis. It is involved in induction of the inflammatory cascade as well as processes destructive to joints, including osteoclast activation and synoviocyte proliferation.
The sole IL-1 inhibitor on the market--anakinra (Kineret), an IL-1 receptor antagonist--requires daily subcutaneous administration. IL-1 trap binds tightly to IL-1 and offers the advantage of once-weekly therapy.
Dr. Bingham reported on 201 patients with long-standing moderate to severe active rheumatoid arthritis who were randomized to 25, 50, or 100 mg/wk of IL-1 trap or placebo in a 12-week, double-blind, 38-center study sponsored by Regeneron Pharmaceuticals.
Overall, 46% of patients on the 100-mg dose attained at least a 20% reduction in disease signs and symptoms by American College of Rheumatology criteria, or ACR 20, compared with an unusually high 31% in the placebo arm, said Dr. Bingham of the Hospital for Joint Diseases, New York.
Both C-reactive protein and the erythrocyte sedimentation rate fell swiftly and dramatically in dose-dependent fashion. The Disease Activity Score-28 (DAS-28) decreased by a mean 1.12 points from a baseline value in excess of 5.5 in the 100-mg group. The most common adverse events involved injection site reactions, which affected 34% of subjects.
BY BRUCE JANCIN
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Article Type:||Brief Article|
|Date:||Nov 15, 2004|
|Previous Article:||Conivaptan may promote normalized sodium levels.|
|Next Article:||Tazarotene deemed 'nonapprovable' for psoriasis: risk management plans, noninferiority data, and chance of off-label uses were among FDA's concerns.|